(GL) Globe Life - Ratings and Ratios

Globe Life Inc. (NYSE:GL) operates as a holding company specializing in life and supplemental health insurance products, along with annuity solutions. The company primarily targets lower middle- and middle-income households across the United States. Its business is organized into three core segments: Life Insurance, Supplemental Health Insurance, and Investments. The Life Insurance segment offers whole life, term life, and other life insurance products designed to provide long-term financial protection. The Supplemental Health Insurance segment focuses on Medicare supplement policies and limited-benefit health insurance products, including coverage for accidents, cancer, critical illness, heart conditions, and intensive care. The Investments segment manages the company’s portfolio, which includes fixed-income securities and other investment assets.

The company distributes its products through multiple channels, including a direct-to-consumer division, exclusive agencies, and a network of independent agents. This multi-channel approach allows Globe Life to reach a broad audience and maintain a strong market presence. Formerly known as Torchmark Corporation, the company rebranded as Globe Life Inc. in August 2019 to align its corporate identity with its flagship life insurance brand. Founded in 1900 and headquartered in McKinney, Texas, Globe Life has established a long-standing reputation for providing affordable insurance solutions to its target demographic.

From a technical perspective, Globe Life’s stock has shown stability with a 20-day average volume of 606,680 shares. The stock is currently trading at $122.79, slightly below its 20-day SMA of $123.41 but above its 200-day SMA of $109.59, indicating recent upward momentum. The average true range (ATR) of 4.54 suggests moderate volatility. On the fundamental side, the company’s market capitalization stands at $10.93 billion, with a trailing P/E ratio of 10.15 and a forward P/E of 10.44, signaling undervaluation relative to future earnings expectations. The price-to-book (P/B) ratio of 1.90 and price-to-sales (P/S) ratio of 1.75 align with industry averages, while the return on equity (RoE) of 20.18% reflects strong profitability.